Document:

Exhibit 10.1

 

EXECUTION VERSION

 

SECURITIES PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 19, 2020, by and among KULR TECHNOLOGY
GROUP, INC., a Delaware corporation (the “Company”), and YA II PN, LTD., a Cayman Islands exempt
company (“Investor”).

 

WITNESSETH

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to the Investor, and the Investor,
desires to purchase from the Company, securities of the Company as more fully described in this Agreement;

 

WHEREAS,
the Company has authorized the designation of that certain Series D convertible preferred stock, par value $0.0001 per share (the
 “Series D Preferred Shares”), which shall be convertible into shares of the Company’s Common Stock, par
value $0.0001 per share (the “Common Stock”), in accordance with the terms of the Company’s Certificate of Designations
of the Series D Preferred Stock attached hereto as Exhibit A (the “Certificate of Designations”);

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Investor
and the Investor shall purchase 650 shares of Series D Preferred Shares at stated value of $10,000 per share, which shall be convertible
into shares of Common Stock (as converted, the “Conversion Shares”) and 1,300,000 shares of the Company’s Common
Stock (the “Commitment Shares”) for a purchase for a purchase price of $6,500,000 (the “Purchase Price”)
within 1 business day following the date hereof, subject to notification of satisfaction of the conditions to the closing set forth herein
and in Sections 7 and 8 herein (the “Closing” or “Closing Date”), (the “Purchase Price”);

 

WHEREAS,
contemporaneously with the Closing the Company shall issue to the Investor a warrant to purchase 2,600,000 shares of the Company’s
Common Stock (the “Warrant Shares”) in the form attached hereto as Exhibit B (the “Warrant”);

 

WHEREAS,
contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering Irrevocable Transfer
Agent Instructions (the “Irrevocable Transfer Agent Instructions”); and

 

WHEREAS,
the Series D Preferred Shares, the Conversion Shares, the Commitment Shares, the Warrant and the Warrant Shares are collectively
referred to herein as the “Securities.”

 

    

    

    

 

NOW,
THEREFORE, in consideration of the mutual covenants and other agreements contained in this Agreement the Company and the Investor
hereby agree as follows:

 

1.            CERTAIN
DEFINITIONS.

 

(a)            “Anti-Bribery
Laws” shall mean of any provision of any applicable law or regulation implementing the OECD Convention on Combating Bribery
of Foreign Public Officials in International Business Transactions or any applicable provision of the U.S. Foreign Corrupt Practices Act
of 1977, as amended (the “FCPA”), the U.K. Bribery Act 2010, or any other similar law of any other jurisdiction in
which the Company operates its business, including, in each case, the rules and regulations thereunder.

 

(b)            “Applicable
Laws” shall mean applicable laws, statutes, rules, regulations, orders, executive orders, directives, policies, guidelines,
ordinance or regulation of any governmental entity and codes having the force of law, whether local, national, or international, as amended
from time to time, including without limitation (i) all applicable laws that relate to money laundering, terrorist financing, financial
record keeping and reporting, (ii) all applicable laws that relate to anti-bribery, anti-corruption, books and records and internal
controls, including the Anti-Bribery Laws, (iii) OFAC and any Sanctions Laws or Sanctions Programs, and (iv) CAATSA and any
CAATSA Sanctions Programs, Anti-Money Laundering Laws.

 

(c)            “BHCA”
shall mean the Bank Holding Company Act of 1956, as amended.

 

(d)            “CAATSA”
shall mean Public Law No. 115-44 The Countering America’s Adversaries Through Sanctions Act.

 

(e)            “CAATSA
Sanctions Programs” shall mean a country or territory that is, or whose government is, the subject of sanctions imposed by CAATSA.

 

(f)             “Anti-Money
Laundering Laws” shall mean applicable financial recordkeeping and reporting requirements and all other applicable U.S. and
non-U.S. anti-money laundering laws, rules and regulations, including, but not limited to, those of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the United States Bank Secrecy Act, as amended by the USA PATRIOT Act of 2001, and the United States
Money Laundering Control Act of 1986 (18 U.S.C. §§1956 and 1957), as amended, as well as the implementing rules and regulations
promulgated thereunder, and the applicable money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency or self-regulatory.

 

(g)            “OFAC”
shall mean the U.S. Department of Treasury’s Office of Foreign Asset Control.

 

(h)            “Sanctioned
Country” shall mean a country or territory that is the subject or target of a comprehensive embargo or Sanctions Laws prohibiting
trade with the country or territory, including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria.

 

(i)             “Sanctions
Laws” shall mean any sanctions administered or enforced by OFAC or the U.S. Departments of State or Commerce and including,
without limitation, the designation as a “Specially Designated National” or on the “Sectoral Sanctions Identifications
List”, collectively “Blocked Persons”), the United Nations Security Council (“UNSC”), the European
Union, Her Majesty's Treasury (“HMT”) or any other relevant sanctions authority.

 

    2

    

    

 

(j)            “Sanctions
Programs” shall mean any OFAC, HMT or UNSC economic sanction program including, without limitation, programs related to a Sanctioned
Country.

 

(k)            “Sarbanes-Oxley
Act” means the Sarbanes-Oxley Act of 2002, as amended.

 

2.            ISSUANCE
OF SERIES D PREFERRED SHARES AND RELATED TRANSACTIONS.

 

(a)            Issuance
of Series D Preferred Shares, Commitment Shares. Subject to the satisfaction (or waiver) of the conditions to the Closing set
forth in Sections 6 and 7 below, the Company shall issue and sell to the Investor, and the Investor agrees to purchase from the Company
at the Closing the Series D Preferred Shares and the Commitment Shares.

 

(b)            Closing
Date. The Closing of the purchase of the Series D Preferred Shares and Commitment Shares by the Investor shall occur at the offices
Yorkville Advisors Global, LP, 1012 Springfield Avenue, Mountainside, NJ 07092. The date and time of the Closing shall be 10:00 a.m.,
New York time, on the 1st Business Day on which the conditions to the Closing set forth in Sections 7 and 8 below are satisfied
or waived (or such other date as is mutually agreed to by the Company and the Investor) (the “Closing Date”). As used
herein “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks in New York,
New York are authorized or required by law to remain closed.

 

(c)            Form of
Payment; Deliveries. Subject to the satisfaction of the terms and conditions of this Agreement, on the Closing Date, (i) the
Investor shall deliver to the Company the Purchase Price for the Series D Preferred Shares and the Commitment Shares to be issued
and sold to the Investor at the Closing, minus the fees to be paid directly from the proceeds of the Closing as set forth herein (if any),
and (ii) the Company shall deliver to the Investor, Series D Preferred Shares and the Commitment Shares which the Investor is
purchasing at the Closing.

 

3.            INVESTOR’S
REPRESENTATIONS AND WARRANTIES.

 

The Investor represents and
warrants, that:

 

(a)            Investment
Purpose. The Investor is acquiring the Securities for its own account for investment only and not with a view towards, or for resale
in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the Securities Act;
provided, however, that by making the representations herein, the Investor reserves the right to dispose of the Securities at any time
in accordance with or pursuant to an effective registration statement covering such Securities or an available exemption under the Securities
Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of
the Securities.

 

    3

    

    

 

(b)            Transfer
or Resale. The Investor understands that the Securities are registered pursuant to an effective registration statement. If the Securities
cease to be registered they the Securities may only be offered for sale, sold, assigned or transferred if: (A) subsequently registered
thereunder, (B) the Investor shall have delivered to the Company an opinion of counsel, in a generally acceptable form, to the effect
that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration
requirements, or (C) the Investor provides the Company with reasonable assurances (in the form of seller and broker representation
letters) that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the Securities
Act, as amended (or a successor rule thereto) (collectively, “Rule 144”), in each case following the applicable
holding period set forth therein; (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance
with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which
the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities
Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder;
and (iii) neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or
any state securities laws or to comply with the terms and conditions of any exemption thereunder.

 

(c)            Information.
The Investor and its advisors (and his or, its counsel), if any, have been furnished with all materials relating to the business, finances
and operations of the Company and information he deemed material to making an informed investment decision regarding the purchase of the
Securities, which have been requested by the Investor. The Investor and its advisors, if any, have been afforded the opportunity to ask
questions of the Company and its management. Neither such inquiries nor any other due diligence investigations conducted by the Investor
or its advisors, if any, or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s
representations and warranties contained in Section 4 below. The Investor understands that its investment in the Securities involves
a high degree of risk. The Investor is in a position regarding the Company, which, based upon employment, family relationship or economic
bargaining power, enabled and enables the Investor to obtain information from the Company in order to evaluate the merits and risks of
this investment. The Investor has sought such accounting, legal and tax advice, as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Securities.

 

(d)            Organization;
Authority. The Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
(as defined below) to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

(e)            Authorization,
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid
and binding agreement of the Investor enforceable in accordance with its terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

    4

    

    

 

(f)            No
Conflicts. The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of the transactions
contemplated hereby will not (i) result in a violation of the organizational documents of the Investor, (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Investor is a party or
(iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws)
applicable to the Investor, except, in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations
which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Investor
to perform its obligations hereunder.

 

(g)           Certain
Trading Activities. The Investor has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with the Investor, engaged in any transactions in the securities of the Company (including, without limitation, any Short Sales (as defined
below) involving the Company's securities). The Investor hereby agrees that it shall not directly or indirectly, engage in any Short Sales
involving the Company’s securities during the period commencing on the date hereof and ending when the Investor no longer holds
Securities. “Short Sales” means all "short sales" as defined in Rule 200 promulgated under Regulation SHO under
the 1934 Act (as defined below). The Investor is aware that Short Sales and other hedging activities may be subject to applicable federal
and state securities laws, rules and regulations and the Investor acknowledges that the responsibility of compliance with any such
federal or state securities laws, rules and regulations is solely the responsibility of the Investor.

 

(h)           Trading
Information. On a weekly basis, the Investor agrees to provide the Company with trading reports setting forth the number and average
sales prices of Conversion Shares sold the Investor during the prior trading week.

 

(i)            Investor’s
Status. The Investor is not (i) an officer or director of the Company or any of its Subsidiaries, (ii) an "affiliate"
(as defined in Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”))
of the Company or any of its Subsidiaries or (iii) a “beneficial owner” of more than 10% of the Ordinary Shares (as defined
for purposes of Rule 13d-3 of the 1934 Act). The Investor further represents that it is not (nor any affiliate of Investor) acting
as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated hereby and thereby, and any advice given by the Investor or any of its representatives or
agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor's
purchase of the Securities.

 

(j)            The
Investor shall not and agrees not to offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction
which is designed to, or might reasonably be expected to, result in the disposition, whether by actual disposition or effective economic
disposition due to cash settlement or otherwise) by the Investor or any affiliate of the Investor or any person in privity with the Investor
or any affiliate of the Investor), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease
a call equivalent position within the meaning of Section 16 of the Exchange Act, with respect to, any of the Securities beneficially
owned, held or hereafter acquired by the undersigned until the earlier to occur of: i) the Company’s Common Stock is listed or quoted
on a national securities exchange or ii) June 4, 2021.

 

    5

    

    

 

4.            REPRESENTATIONS
AND WARRANTIES OF THE COMPANY AND SUBSIDIARIES.

 

Except as set forth under
the corresponding section of the Disclosure Schedules which Disclosure Schedules shall be deemed a part hereof and to qualify any representation
or warranty otherwise made herein to the extent of such disclosure, the Company hereby makes the representations and warranties set forth
below to the Investor:

 

(a)            Subsidiaries.
All of the direct and indirect subsidiaries of the Company are set forth on Schedule 4(a). The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each subsidiary free and clear of any liens, and all the issued and outstanding
shares of capital stock of each subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.

 

(b)            Security
Interests Granted. Except as set forth on Disclosure Schedule
4(b). there are no material security interests granted, issued or allowed to exist in any assets of the Company or subsidiary.

 

(c)            Organization
and Qualification. The Company and its subsidiaries are corporations duly organized and validly existing in good standing under the
laws of the jurisdiction in which they are incorporated, and have the requisite corporate power to own their properties and to carry on
their business as now being conducted. Each of the Company and its subsidiaries is duly qualified as a foreign corporation to do business
and is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have or reasonably be expected to result in
(i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no
proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power
and authority or qualification.

 

(d)            Authorization,
Enforcement, Compliance with Other Instruments. (i) The Company has the requisite corporate power and authority to enter into
and perform its obligations under this Agreement, the Warrant, the Irrevocable Transfer Agent Instructions, to file the Certificate of
Designation and each of the other agreements entered into by the parties hereto in connection with the transactions contemplated by this
Agreement (collectively the “Transaction Documents”) and to issue the Securities in accordance with the terms hereof
and thereof, (ii) the execution and delivery of the Transaction Documents by the Company and the consummation by it of the transactions
contemplated hereby and thereby, including, without limitation, the issuance of the Securities, the reservation for issuance and the issuance
of the Conversion Shares and Warrant Shares have been duly authorized by the Company’s Board of Directors and no further consent
or authorization is required by the Company, its Board of Directors or its stockholders, (iii) the Transaction Documents have been
duly executed and delivered by the Company, (iv) the Transaction Documents constitute the valid and binding obligations of the Company
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of
equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally,
the enforcement of creditors’ rights and remedies. The authorized officer of the Company executing the Transaction Documents knows
of no reason why the Company cannot perform any of the Company’s other obligations under the Transaction Documents.

 

    6

    

    

 

(e)            Capitalization.
The authorized capital stock of the Company consists of 500,000,000 of shares of Common Stock of which 92,947,200 shares are issued and
outstanding, 1,000,000 shares Class A Preferred Stock of which -0- are issued and outstanding, 31,000 shares Class B Preferred
Stock of which -0- are issued and outstanding, and 400 shares Class C Preferred Stock of which -0- are issued and outstanding. All
of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except as disclosed in Schedule 4(e): (i) none of the Company's capital stock
is subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) other
than those disclosed in the SEC filings, there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock
of the Company or any of its subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its
subsidiaries is or may become bound to issue additional capital stock of the Company or any of its subsidiaries or options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into,
or exercisable or exchangeable for, any capital stock of the Company or any of its subsidiaries; (iii) other than those disclosed
in the SEC filings, there are no outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents
or instruments evidencing indebtedness of the Company or any of its subsidiaries or by which the Company or any of its subsidiaries is
or may become bound; (iv) there are no financing statements securing obligations in any material amounts, either singly or in the
aggregate, filed in connection with the Company or any of its subsidiaries; (v) there are no outstanding securities or instruments
of the Company or any of its subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any of its subsidiaries is or may become bound to redeem a security of the Company
or any of its subsidiaries; (vi) there are no securities or instruments containing anti-dilution or similar provisions that will
be triggered by the issuance of the Securities; (vii) the Company does not have any stock appreciation rights or "phantom stock"
plans or agreements or any similar plan or agreement; and (viii) the Company and its subsidiaries have no liabilities or obligations
required to be disclosed in the SEC Documents but not so disclosed in the SEC Documents, other than those incurred in the ordinary course
of the Company's or its subsidiaries' respective businesses and which, individually or in the aggregate, do not or would not have a Material
Adverse Effect. The Company has furnished to the Investor true, correct and complete copies of the Company's Certificate of Incorporation,
as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company's Bylaws, as amended
and as in effect on the date hereof (the “Bylaws”), and the terms of all securities convertible into, or exercisable
or exchangeable for, shares of Common Stock and the material rights of the holders thereof in respect thereto. No further approval or
authorization of any stockholder, the Board of Directors of the Company or others is required for the issuance and sale of the Securities.
There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 

    7

    

    

 

(f)            Issuance
of Securities. The issuance of the Series D Preferred Shares, the Commitment Shares and the Warrant are duly authorized and free
from all taxes, liens and charges with respect to the issue thereof. Upon conversion in accordance with the terms of a Series D Preferred
Shares and/or the exercise of the Warrant, the Conversion Shares and/or the Warrant Shares, respectively, when issued will be validly
issued, fully paid and nonassessable, free from all taxes, liens and charges with respect to the issue thereof. The Company has reserved
from its duly authorized capital stock the appropriate number of shares of Common Stock as set forth in this Agreement.

 

(g)            No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Series D Preferred Shares,
and reservation for issuance and issuance of the Conversion Shares and Warrant Shares will not (i) result in a violation of any certificate
of incorporation, certificate of formation, any certificate of designations or other constituent documents of the Company or any of its
subsidiaries, any capital stock of the Company or any of its subsidiaries or bylaws of the Company or any of its subsidiaries or (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
the Company or any of its subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or
decree (including foreign, federal and state securities laws and regulations and the rules and regulations of the OTC Markets’
OTCQB® Market (the “Primary Market”) applicable to the Company or any of its subsidiaries or by which
any property or asset of the Company or any of its subsidiaries is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. The
business of the Company and its subsidiaries is not being conducted, and shall not be conducted in violation of any material law, ordinance,
or regulation of any governmental entity. Except as specifically contemplated by this Agreement and as required under the Securities Act
and any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make any filing
or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under or
contemplated by this Agreement or the Transaction Documents in accordance with the terms hereof or thereof. All consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the date hereof. The Company and its subsidiaries are unaware of any facts or circumstance, which might give rise to any
of the foregoing.

 

    8

    

    

 

(h)            Initial
Registration Statement. The Company has filed, in accordance with the provisions of the Securities Act and the rules and regulations
thereunder, with the SEC a shelf registration statement on Form S-3 (File Number 333-232614) (the “Initial Registration
Statement”) including a base prospectus (such base prospectus included in the Initial Registration Statement, as supplemented
or amended from time to time shall be referred to herein as the “Prospectus”), with respect to the issuance and sale
of securities by the Company, including Common Stock and derivative securities that may be convertible into Common Stock, which contains,
among other things a Plan of Distribution section disclosing the methods by which the Company may sell such securities. The Initial Registration
Statement was declared effective on August 1, 2019 and remains in effect on the date hereof. Except where the context otherwise requires,
the Initial Registration Statement, as amended when it became effective, including all documents filed as part thereof or incorporated
by reference therein, and including any information contained in a Prospectus subsequently filed with the SEC pursuant to Rule 424(b) under
the Securities Act or deemed to be a part of the Initial Registration Statement pursuant to Rule 430B of the Securities Act, is herein
called the “Registration Statement.” No stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Prospectus has been issued by the SEC and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the SEC. At the time the Registration Statement became effective, at the date of
this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material
respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and
any amendments or supplements thereto, at time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date,
conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Company is, and was at the time of the filing of the Registration Statement, eligible
to use Form S-3 under the Securities Act, and the Company meets the transaction requirements with respect to the aggregate market
value of securities being sold pursuant to this offering.

 

    9

    

    

 

(i)            SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by it with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)
during the 2 years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(all of the foregoing filed within the 2 years preceding the date hereof as amended after the date hereof and all exhibits included therein
and financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred to as the “SEC
Documents”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Document prior
to the expiration of any such extension (including pursuant to SEC from 12b-25). The Company has delivered to the Investor or its representatives,
or made available through the SEC’s website at http://www.sec.gov, true and complete copies of the SEC Documents. As of their respective
dates, the SEC Documents complied in all material respects with the requirements of the Exchange Act and the rules and regulations
of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the
SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective
dates, the financial statements of the Company and its subsidiaries included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved
(except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material
respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). No other information provided by or on
behalf of the Company to the Investor which is not included in the SEC Documents contains any untrue statement of a material fact or omits
to state any material fact necessary in order to make the statements therein, in the light of the circumstance under which they are or
were made, not misleading.

 

(j)            10(b)-5.
The SEC Documents when filed, did not include any untrue statements of material fact, nor did they omit to state any material fact required
to be stated therein necessary to make the statements made, in light of the circumstances under which they were made, not misleading.

 

(k)            Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation of which the Company is aware before or by any court,
public board, government agency, self-regulatory organization or body pending against or affecting the Company, the Common Stock or any
of the Company’s subsidiaries, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect.

 

(l)            CAATSA.
Neither the Company or its subsidiaries, nor, to Company’s knowledge, any director, officer, agent, employee or affiliate of the
Company or subsidiaries, is a Person that is, or is owned or controlled by a Person that has a place of business in, or is operating,
organized, resident or doing business in a country or territory that is, or whose government is, the subject of the CAATSA Sanctions Programs.

 

(m)           Sarbanes-Oxley
Act. The Company and its subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act, that are
effective as of the date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are applicable
to the Company and its subsidiaries and effective as of the date hereof.

 

(n)            BHCA.
Neither the Company nor any of its subsidiaries or affiliates is subject to BHCA and to regulation by the Board of Governors of the Federal
Reserve System (the “Federal Reserve). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly
or indirectly, 5% or more of the outstanding shares of any class of voting securities or 25% or more of the total equity of a bank or
any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its subsidiaries or affiliates
exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation
by the Federal Reserve.

 

    10

    

    

 

(o)            No
Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants and lawyers which could affect the Company's ability to perform any of its
obligations under any of the Transaction Documents.

 

(p)            Compliance
with Applicable Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance Applicable
Laws and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the
Company or any of its Subsidiaries with respect to Applicable Laws is pending or, to the knowledge of the Company, threatened.

 

(q)            No
Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, nor any director, officer, employee, agent, affiliate
or other person associated with or acting on behalf of the Company or any of its subsidiaries or affiliates is, or is directly or indirectly
owned or controlled by, a Person that is currently the subject or the target of any Sanctions Laws or is a Blocked Person; neither the
Company, any of its subsidiaries, nor any director, officer, employee, agent, affiliate or other person associated with or acting on behalf
of the Company or any of its subsidiaries or affiliates, is located, organized or resident in a country or territory that is the subject
or target of a comprehensive embargo, Sanctions Laws or Sanctions Programs prohibiting trade with a Sanctioned Country; the Company maintains
in effect and enforces policies and procedures designed to ensure compliance by the Company and its Subsidiaries with applicable Sanctions
Laws and Sanctions Programs; neither the Company, any of its subsidiaries, nor any director, officer, employee, agent, affiliate or other
person associated with or acting on behalf of the Company or any of its subsidiaries or affiliates, acting in any capacity in connection
with the operations of the Company, conducts any business with or for the benefit of any Blocked Person or engages in making or receiving
any contribution of funds, goods or services to, from or for the benefit of any Blocked Person, or deals in, or otherwise engages in any
transaction relating to, any property or interests in property blocked or subject to blocking pursuant to any applicable Sanctions Laws
or Sanctions Programs; no action of the Company or any of its subsidiaries in connection with (i) the execution, delivery and performance
of this Agreement and the other Transaction Documents, (ii) the issuance and sale of the Securities, or (iii) the direct or
indirect use of proceeds from the Securities or the consummation of any other transaction contemplated hereby or by the other Transaction
Documents or the fulfillment of the terms hereof or thereof, will result in the proceeds of the transactions contemplated hereby and by
the other Transaction Documents being used, or loaned, contributed or otherwise made available, directly or indirectly, to any subsidiary,
joint venture partner or other person or entity, for the purpose of (i) unlawfully funding or facilitating any activities of or business
with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions Laws or Sanctions Programs, (ii) unlawfully
funding or facilitating any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in
a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise)
of Sanctions Laws or Sanctions Programs. For the past 5 years, the Company and its subsidiaries have not knowingly engaged in and are
not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the
subject or the target of Sanctions Laws, Sanctions Programs or with any Sanctioned Country.

 

    11

    

    

 

(r)            No
Conflicts with Anti-Bribery Laws. Neither the Company nor any of the subsidiaries has made any contribution or other payment to any
official of, or candidate for, any federal, state or foreign office in violation of any law. Neither the Company, nor any of its subsidiaries
or affiliates, nor any director, officer, agent, employee or other person associated with or acting on behalf of the Company, or any of
its subsidiaries or affiliates, has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful expense
relating to political activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic government official
or employee, to any employee or agent of a private entity with which the Company does or seeks to do business (a “Private Sector
Counterparty”) or to foreign or domestic political parties or campaigns, (iii) violated or is in violation of any provision
of any Anti-Bribery Laws, (iv) taken, is currently taking or will take any action in furtherance of an offer, payment, gift or anything
else of value, directly or indirectly, to any person while knowing that all or some portion of the money or value will be offered, given
or promised to anyone to improperly influence official action, to obtain or retain business or otherwise to secure any improper advantage
or (v) otherwise made any offer, bribe, rebate, payoff, influence payment, unlawful kickback or other unlawful payment; the Company
and each of its respective subsidiaries has instituted and has maintained, and will continue to maintain, policies and procedures reasonably
designed to promote and achieve compliance with the laws referred to in (iii) above and with this representation and warranty; none
of the Company, nor any of its subsidiaries or affiliates will directly or indirectly use the proceeds of the Securities or lend, contribute
or otherwise make available such proceeds to any subsidiary, affiliate, joint venture partner or other person or entity for the purpose
of financing or facilitating any activity that would violate the laws and regulations referred to in (iii) above; to the knowledge
of the Company, there are, and have been, no allegations, investigations or inquiries with regard to a potential violation of any Anti-Bribery
Laws by the Company, its subsidiaries or affiliates, or any of their respective current or former directors, officers, employees, stockholders,
representatives or agents, or other persons acting or purporting to act on their behalf.

 

(s)            No
Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the
1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company's
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”
and, together, “Issuer Covered Persons”) is subject to any of the "Bad Actor" disqualifications described
in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered
Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Investor a copy of any disclosures provided thereunder.

 

    12

    

    

 

(t)            Acknowledgment
Regarding Investor’s Purchase of the Series D Preferred Shares, the Commitment Shares and the Warrant. The Company acknowledges
and agrees that the Investor is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the
transactions contemplated hereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given
by the Investor or any of their respective representatives or agents in connection with this Agreement and the transactions contemplated
hereby is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor that the
Company’s decision to enter into this Agreement has been based solely on the independent evaluation by the Company and its representatives.

 

(u)           No
General Solicitation. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with
the offer or sale of the Securities.

 

(v)           No
Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require
registration of the Securities under the Securities Act or cause this offering of the Securities to be integrated with prior offerings
by the Company for purposes of the Securities Act.

 

(w)           Employee
Relations. Neither the Company nor any of its subsidiaries is involved in any labor dispute or, to the knowledge of the Company or
any of its subsidiaries, is any such dispute threatened. None of the Company’s or its subsidiaries’ employees is a member
of a union and the Company and its subsidiaries believe that their relations with their employees are good.

 

(x)           Intellectual
Property Rights. The Company and its subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as now conducted. The Company and its subsidiaries do not have
any knowledge of any infringement by the Company or its subsidiaries of trademark, trade name rights, patents, patent rights, copyrights,
inventions, licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, and, to
the knowledge of the Company there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge,
being threatened against, the Company or its subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright,
license, service names, service marks, service mark registrations, trade secret or other infringement; and the Company and its subsidiaries
are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

(y)           Environmental
Laws. The Company and its subsidiaries are (i) in compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of
them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions
of any such permit, license or approval.

 

    13

    

    

 

(z)            Title.
All real property and facilities held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company and its subsidiaries.

 

(aa)          Insurance.
The Company and each of its subsidiaries is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its subsidiaries
are engaged. Neither the Company nor any such subsidiary has been refused any insurance coverage sought or applied for and neither the
Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that
would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations of the Company
and its subsidiaries, taken as a whole.

 

(bb)          Regulatory
Permits. The Company and its subsidiaries possess all material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such
subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or
permit.

 

(cc)          Internal
Accounting Controls. The Company and each of its subsidiaries maintains a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting
principles and to maintain asset accountability, and (iii) the recorded amounts for assets are compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences; provided however, that the Company disclosed
in its form 10-K for the period ended December 31, 2020, that management had determined that its internal accounting controls were
not effective as of December 31, 2020.

 

(dd)          No
Material Adverse Breaches, etc. Neither the Company nor any of its subsidiaries is subject to any charter, corporate or other
legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers has or
is expected in the future to have a Material Adverse Effect on the business, properties, operations, financial condition, results of operations
or prospects of the Company or its subsidiaries. Neither the Company nor any of its subsidiaries is in breach of any contract or agreement
which breach, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect on the business, properties,
operations, financial condition, results of operations or prospects of the Company or its subsidiaries.

 

    14

    

    

 

 

(ee)          Tax
Status. The Company and each of its subsidiaries has made and filed all federal and state income and all other tax returns, reports
and declarations required by any jurisdiction to which it is subject and (unless and only to the extent that the Company and each of its
subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) has paid all
taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for the payment
of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for
any such claim.

 

(ff)           Certain
Transactions. Except for arm’s length transactions pursuant to which the Company makes payments in the ordinary course of business
upon terms no less favorable than the Company could obtain from third parties and other than the grant of stock options disclosed in the
SEC Documents, none of the officers, directors, or employees of the Company is presently a party to any transaction with the Company (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

(gg)          Except
with respect to the material terms and conditions of the transactions contemplated by this Agreement, all of which shall be publicly disclosed
by the Company as soon as possible after the date hereof, the Company covenants and agrees that neither the Company, nor any other person
acting on its behalf, will provide the Investor or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto the Investor shall have entered into a written agreement with the Company regarding the confidentiality
and use of such information. The Company understands and confirms that the Investor shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.

 

(hh)          Fees
and Rights of First Refusal. Except as disclosed in the SEC Documents, the Company is not obligated to offer the securities offered
hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former shareholders
of the Company, underwriters, brokers, agents or other third parties.

 

(ii)            Investment
Company. The Company is not, and is not an affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become subject to the Investment Company Act.

 

    15

    

    

 

(jj)            Registration
Rights. Except as disclosed in the SEC Documents, no Person has any right to cause the Company to effect the registration under the
Securities Act of any securities of the Company. There are no outstanding registration statements not yet declared effective and there
are no outstanding comment letters from the SEC or any other regulatory agency.

 

(kk)          Private
Placement. Assuming the accuracy of the Investor’s representations and warranties set forth in Section 3, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Investor as contemplated hereby. The
issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Primary Market.

 

(ll)            Listing
and Maintenance Requirements. The Company has not, in the 12 months preceding the date hereof, received notice from the Primary Market
on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Primary Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue
to be, in compliance with all such listing and maintenance requirements.

 

(mm)        Reporting
Status.  With a view to making available to the Investor the benefits of Rule 144 or any similar rule or regulation
of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration, and as a material
inducement to the Investor’s purchase of the Securities, the Company represents and warrants that: (i) the Company is, and
has been for a period of at least 90 days immediately preceding the date hereof, subject to the reporting requirements of section 13 or
15(d) of the Exchange Act (ii) the Company has filed all required reports under section 13 or 15(d) of the Exchange Act,
as applicable, during the 12 months preceding the date hereof (or for such shorter period that the Company was required to file such reports),
(iii) it is not an issuer defined as a “Shell Company,” and (iv) it is not an issuer that has been at any time previously
an issuer defined as a “Shell Company.” For the purposes hereof, the term “Shell Company” shall mean an issuer
that meets the description defined in paragraph (i)(1)(i) of Rule 144.

 

(nn)         Disclosure. 
The Company has made available to the Investor and its counsel all the information reasonably available to the Company that the Investor
or its counsel have requested for deciding whether to acquire the Securities.  No representation or warranty of the Company contained
in this Agreement (as qualified by the Disclosure Schedule) or any of the other Transaction Documents, and no certificate furnished or
to be furnished to the Investor at the Closing, or any due diligence evaluation materials furnished by the Company or on behalf of the
Company, including without limitation, due diligence questionnaires, or any other documents, presentations, correspondence, or information
contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained
herein or therein not misleading in light of the circumstances under which they were made.

 

(oo)         Manipulation
of Price.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement
agent in connection with the placement of the Securities.

 

    16

    

    

 

(pp)         Dilutive
Effect. The Company understands and acknowledges that that its obligation to issue Conversion Shares upon conversion of the Series D
Preferred Shares or issue Warrant Shares upon exercise of the Warrant is absolute and unconditional regardless of the dilutive effect
that such issuance may have on the ownership interests of other stockholders of the Company.

 

(qq)         Relationship
of the Parties. Neither the Company, nor any of its subsidiaries, affiliates, nor any person acting on its or their behalf is a client
or customer of the Investor or any of its affiliates and neither the Investor nor any of its affiliates has provided, or will provide,
any services to the Company or any of its affiliates, its subsidiaries, or any person acting on its or their behalf. The Investor’s
relationship to Company is solely as investor as provided for in the Transaction Documents.

 

5.              COVENANTS.

 

(a)            Best
Efforts. Each party shall use its best efforts to timely satisfy each of the conditions to be satisfied by it as provided in Sections
7 and 8 of this Agreement.

 

(b)            Prospectus
Supplement. On the Closing Date, the Company shall file with the a prospectus supplement pursuant to Rule 424(b) of the
Securities Act (the “Prospectus Supplement”) disclosing all information relating to the transaction contemplated hereby
required to be disclosed therein and an updated Plan of Distribution, including, without limitation, the name of the Investor, a description
of the Securities being offered hereunder, the terms of the offering, and other material terms of the offering, and any other information
or disclosure necessary to register the transactions contemplated herein.

 

(c)            Maintaining
a Registration Statement. So long as Investor holds Series D Preferred Shares, the Commitment Shares, the Warrant, and/or the
Investor holds Conversion Shares and/or Warrant Shares the Company shall maintain the continuous effectiveness of any Registration Statement
with respect to the Conversion Shares to be issued upon conversion of the Series D Preferred Shares, Commitment Shares, the Warrant,
the Warrant Shares to be issued upon exercise of the Warrant, Conversion Shares and/or Warrant Shares held by the Investor (the “Registrable
Securities”) and continue until all such Registrable Securities have been sold or may permanently be sold without any restrictions
pursuant to Rule 144, as determined by the counsel to the Company or the Investor’s Counsel pursuant to a written opinion letter
to such effect, addressed and to the Company’s transfer agent (the “Registration Period”). Notwithstanding anything
to the contrary contained in this Agreement, the Company shall ensure that, when filed, the Registration Statement (including, without
limitation, all amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements
thereto) used in connection with the Registration Statement shall not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light
of the circumstances in which they were made) not misleading.

 

    17

    

    

 

(d)            During
the Registration Period, the Company shall (i) promptly prepare and file with the SEC such amendments (including post-effective
amendments) and supplements to any Registration Statement and the Prospectus used in connection with any Registration Statement, which
Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such Registration
Statement effective at all times during the Registration Period, (ii) prepare and file with the SEC additional Registration Statements
in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to
be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and as so supplemented or amended
to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible to any comments received from the SEC with
respect to a Registration Statement or any amendment thereto and as promptly as reasonably possible provide the Investor true and complete
copies of all correspondence from and to the SEC relating to a Registration Statement (provided that the Company may excise any information
contained therein which would constitute material non-public information as to any Investor which has not executed a confidentiality agreement
with the Company); and (iv) comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities
of the Company covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of
in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. In
the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including
pursuant to this Section 2(d)) by reason of the Company’s filing a report on Form 10-KSB, Form 10-QSB or Form 8-K
or any analogous report under the Exchange Act of 1934, the Company shall incorporate such report by reference into the Registration Statement,
if applicable, or shall file such amendments or supplements with the SEC on the same day on which the Exchange Act report is filed which
created the requirement for the Company to amend or supplement the Registration Statement.

 

(e)            Piggy-Back
Registration Statements. So long as Investor holds Series D Preferred Shares or Registrable Securities and such Registrable Securities
are either not registered for resale pursuant to an effective registration statement or eligible for resale pursuant to an exemption of
the registration requirements of the Securities Act, the Company will not file a registration statement under the Securities Act relating
to securities that are not the Registrable Securities without including the Registrable Securities.

 

(f)             As
promptly as practicable after becoming aware of such event or development, the Company shall notify each Investor in writing of the happening
of any event as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement
of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material,
nonpublic information), and promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement
or omission, and deliver an electronic copy of such supplement or amendment to each Investor, which delivery obligation may be fulfilled
by directing the Investor to www.sec.gov. The Company shall also promptly notify each Investor in writing (i) when a Prospectus or
any Prospectus supplement or post-effective amendment has been filed, and when a Registration Statement or any post-effective amendment
has become effective (notification of such effectiveness shall be delivered to each Investor by facsimile on the same day of such effectiveness),
(ii) of any request by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information,
and (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate.

 

    18

    

    

 

(g)            The
Company shall use its best efforts to (i) register and qualify the Registrable Securities covered by a Registration Statement under
such other securities or “blue sky” laws of such jurisdictions in the United States as any Investor reasonably requests, (ii) prepare
and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications
as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be
necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take
all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however,
that the Company shall not be required in connection therewith or as a condition thereto to (w) make any change to its articles of
incorporation or by-laws, (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but
for this Section 3(c), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to
service of process in any such jurisdiction. The Company shall promptly notify each Investor who holds Registrable Securities of the receipt
by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities
for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice
of the initiation or threat of any proceeding for such purpose.

 

(h)            If,
after the execution of this Agreement, a Investor believes, after consultation with its legal counsel, that it could reasonably be deemed
to be an underwriter of Registrable Securities, at the request of any Investor, the Company shall use its best efforts to furnish to such
Investor, on the date of the effectiveness of the Registration Statement and thereafter from time to time on such dates as a Investor
may reasonably request (i) a letter, dated such date, from the Company’s independent certified public accountants in form and
substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, and
(ii) an opinion, dated as of such date, of counsel representing the Company for purposes of such Registration Statement, in form,
scope and substance as is customarily given in an underwritten public offering, addressed to the Investors.

 

(i)             If,
after the execution of this Agreement, a Investor believes, after consultation with its legal counsel, that it could reasonably be deemed
to be an underwriter of Registrable Securities, at the request of any Investor, the Company shall make available for inspection by (i) any
Investor and (ii) one (1) firm of accountants or other agents retained by the Investors (collectively, the “Inspectors”)
all pertinent financial and other records, and pertinent corporate documents and properties of the Company (collectively, the “Records”),
as shall be reasonably deemed necessary by each Inspector, and cause the Company’s officers, directors and employees to supply all
information which any Inspector may reasonably request; provided, however, that each Inspector shall agree, and each Investor hereby agrees,
to hold in strict confidence and shall not make any disclosure (except to a Investor) or use any Record or other information which the
Company determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (a) the disclosure
of such Records is necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required under
the Securities Act, (b) the release of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court
or government body of competent jurisdiction, or (c) the information in such Records has been made generally available to the public
other than by disclosure in violation of this or any other agreement of which the Inspector and the Investor has knowledge. The Investor
agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction
or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent
disclosure of, or to obtain a protective order for, the Records deemed confidential.

 

    19

    

    

 

(j)             The
Company shall use its best efforts either to cause all the Registrable Securities covered by a Registration Statement (i) to be listed
on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing
of such Registrable Securities is then permitted under the rules of such exchange or (ii) the inclusion for quotation on the
OTC Bulletin Board for such Registrable Securities. The Company shall pay all fees and expenses in connection with satisfying its obligation
under this Section 3(i).

 

(k)            The
Company shall cooperate with each Investor who holds Registrable Securities being offered and, to the extent applicable, to facilitate
the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be
offered pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts, as the case may be,
as the Investors may reasonably request and registered in such names as the Investors may request.

 

(l)             The
Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable Securities
pursuant to a Registration Statement.

 

(m)           The
Company shall not create, issue, or reclassify any existing shares of Common Stock or classes or series of Preferred Shares or capital
stock that (i) are senior to the Series D Preferred Shares or have a liquidation preference over the Series D Preferred
Shares, (ii) contain any dividend or conversion rights that are preferential to the dividend rights of the Series D Preferred
Shares or (iii) are redeemable.

 

(n)            The
Company shall not amend any corporate governance document, including the Certificates of Designation so as to alter or change the powers,
preferences, or special rights of Series D Preferred Shares or otherwise adversely affect the rights and preferences of Series D
Preferred Shares.

 

(o)            Compliance
with Applicable Laws. While the Investor owns any Securities the Company shall comply with all Applicable Laws and will not take any
action which will cause the Investor to be in violation of any such Applicable Laws.

 

    20

    

    

 

(p)            Conduct
of Business. While the Investor owns any Securities, the business of the Company shall not be conducted in violation of Applicable
Laws and will not take any action which will cause the Investor to be in violation of any such Applicable Laws.

 

(q)            While
the Investor owns any Securities, neither the Company, nor any of its Subsidiaries or affiliates, directors, officers, employees, representatives
or agents shall:

 

(i)             conduct
any business or engage in any transaction or dealing with or for the benefit of any Blocked Person, including the making or receiving
of any contribution of funds, goods or services to, from or for the benefit of any Blocked Person;

 

(ii)            deal
in, or otherwise engage in any transaction relating to, any property or interests in property blocked or subject to blocking pursuant
to the applicable Sanctions Laws, Sanctions Programs, located in a Sanctioned Country, or CAATSA or CAATSA Sanctions Programs;

 

(iii)           use
any of the proceeds of the transactions contemplated by this Agreement to finance, promote or otherwise support in any manner any illegal
activity, including, without limitation, in contravention of any Anti-Money Laundering Laws, Sanctions Laws, Sanctioned Program, Anti-Bribery
Laws or in any Sanctioned Country.

 

(iv)           violate,
attempt to violate, or engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding,
any of the Anti-Money Laundering Laws, Sanctions Laws, Sanctions Program, Anti-Bribery Laws, CAATSA or CAATSA Sanctions Programs.

 

(v)            While
the Investor owns any Securities, the Company shall maintain in effect and enforce policies and procedures designed to ensure compliance
by the Company and its Subsidiaries and their directors, officers, employees, agents, representatives and affiliates with Applicable Laws.

 

(vi)           While
any Investor owns any Securities, the Company will promptly notify the Investor in writing if any of the Company, or any of its Subsidiaries
or affiliates, directors, officers, employees, representatives or agents, shall become a Blocked Person, or become directly or indirectly
owned or controlled by a Blocked Person.

 

(vii)          The
Company shall provide such information and documentation it may have as the Investor or any of their affiliates may reasonably request
to satisfy compliance with Applicable Laws.

 

(viii)         The
covenants set forth above shall be ongoing while the Investor owns any Securities. The Company shall promptly notify the Investor in writing
should it become aware during such period (a) of any changes to these covenants, or (b) if it cannot comply with the covenants
set forth herein. The Company shall also promptly notify the Investor in writing during such period should it become aware of an investigation,
litigation or regulatory action relating to an alleged or potential violation of Applicable Laws.

 

    21

    

    

 

(r)             Reporting
Status. With a view to making available to the Investor the benefits of Rule 144 or any similar rule or regulation of the
SEC that may at any time permit the Investor to sell securities of the Company to the public without registration, and as a material inducement
to the Investor’s purchase of the Securities, the Company represents, warrants, and covenants to the following:

 

(i)             The
Company is subject to the reporting requirements of the Exchange Act and has filed all required reports under section 13 or 15(d) of
the Exchange Act during the 12 months prior to the date hereof (or for such shorter period that the issuer was required to file such reports),
other than Form 8-K reports;

 

(ii)            From
the date hereof until all the Registrable Securities either have been sold by the Investor, or may permanently be sold by the Investor
without any restrictions pursuant to Rule 144, (the “Registration Period”) the Company shall be required to file
with the SEC in a timely manner all reports under section 13 or 15(d) of the Exchange Act and such reports shall conform to the requirement
of the Exchange Act and the SEC for filing thereunder;

 

(iii)           The
Company shall furnish to the Investor so long as the Investor owns Securities, promptly upon request, (i) a written statement by
the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly
report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably
requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and

 

(iv)           During
the Registration Period the Company shall not terminate its status as an issuer required to file reports under the Exchange Act even if
the Exchange Act or the rules and regulations thereunder would otherwise permit such termination.

 

(s)            Use
of Proceeds. The Company shall use the proceeds from the issuance of the Series D Preferred Shares and Commitment Shares
hereunder for working capital and other general corporate purposes. So long as the Investor holds Series D Preferred Shares,
the Company shall not pay any related party obligations all of which related party obligations shall be subordinated to the
obligations owed to the Investor, except that the related party obligations and transactions in the ordinary course of business
shall not apply to the prohibition in the Subsection (p). Neither the Company nor any subsidiary shall, directly or indirectly, use
any portion of the proceeds of the transactions contemplated herein, or lend, contribute, facilitate or otherwise make
available such proceeds to any Person (i) to make any payment towards any indebtedness or other obligations of the Company or
subsidiary; (ii) to pay any obligations of any nature or kind due or owing to any officers, directors, employees, or
shareholders of the Company or subsidiary, other than salaries payable in the ordinary course of business of the Company;
(iii) to fund, either directly or indirectly, any activities or business of or with any Blocked Person, in any Sanctioned
Country, (iv) or in any manner or in a country or territory, that, at the time of such funding, is, or whose government is, the
subject of CAATSA Sanctions Programs or (iv) in any other manner that will result in a violation of Anti-Money Laundering Laws,
Sanctions Laws, Sanctioned Program, Anti-Bribery Laws or CAATSA Sanctions Programs.

 

    22

    

    

 

(t)             Reservation
of Shares. On the date hereof, the Company shall reserve for issuance to the Investor 3,170,732 Conversion Shares and 2,600,000 Warrant
Shares (the “Share Reserve”). The Company represents that it has sufficient authorized and unissued shares of Common
Stock available to create the Share Reserve after considering all other commitments that may require the issuance of Common Stock. The
Company shall take all action reasonably necessary to at all times have authorized, and reserved for the purpose of issuance, such number
of Conversion Shares and Warrant Shares as shall be necessary to affect the full conversion of the Series D Preferred Shares and
the Warrant. If at any time the Share Reserve is insufficient to affect the full conversion of the Series D Preferred or exercise
of the Warrant the Company shall increase the Share Reserve accordingly. If the Company does not have sufficient authorized and unissued
shares of Common Stock available to increase the Share Reserve, the Company shall call and hold a special meeting of the shareholders
within 30 days of such occurrence, for the sole purpose of increasing the number of shares authorized. The Company’s management
shall recommend to the shareholders to vote in favor of increasing the number of shares of Common Stock authorized.

 

(u)            Listings
or Quotation. The Company’s Common Stock shall be listed or quoted for trading on the Primary Market. The Company shall promptly
secure the listing of all of the Securities upon each national securities exchange and automated quotation system, if any, upon which
the Common Stock is then listed (subject to official notice of issuance) and shall maintain such listing of all Registrable Securities
from time to time issuable under the terms of the Transaction Documents.

 

(v)            Obligation
to Obtain Shareholder Approval. In the event that the Company’s Common Stock shall become listed on a market other than the
Primary Market and the Company is unable to issue Conversion Shares and or Warrant Shares to the Investor as a result of such issuance
of Common Stock being in excess of the aggregate number of shares of Common Stock that the Company may issue under the rules or regulations
of such market, or any other applicable rule or limitation, the Company, shall no later than 30 calendar days of the date of such
conversion or exercise notice obtain the approval of its stockholders or approval of such market, as required by the applicable rules of
such market, to issue such shares of Common Stock issuable as Conversion Shares and or Warrant Shares.

 

(w)           Shareholder
Votes. Should the Company require approval of its stockholders, including but not limited pursuant to Section (t) above
to enter into this transaction and or issue the Conversion Shares and or Warrant Shares, the Company shall recommend that its shareholders
vote in favor of such issuance of Conversion Shares and or Warrant Shares or to enter into this transaction.

 

(x)            Fees
and Expenses.

 

(i)             The
Company shall pay all of its costs and expenses incurred by it connection with the negotiation, investigation, preparation, execution
and delivery of the Transaction Documents.

 

    23

    

    

 

(ii)            The
Company shall pay to YA Global II SPV, LLC, an affiliate of the Investor and as its designee (the “Designee”), a due
diligence and structuring fee of $10,000 direct from the gross proceeds of the Closing.

 

(iii)           On
the Closing Date the Company shall issue to the Investor the Warrant to purchase 2,600,000 Warrant Shares at an exercise price of $2.50
for a period of 1 year from the date hereof in the form attached here to as Exhibit B.

 

(y)            Corporate
Existence. So long as Series D Preferred and/or Commitment Shares are held by the Investor, the Company shall not directly or
indirectly consummate any merger, reorganization, restructuring, reverse stock split consolidation, sale of all or substantially all of
the Company’s assets or any similar transaction or related transactions (each such transaction, an “Organizational Change”)
unless, prior to the consummation an Organizational Change, the Company obtains the written consent of the Investor. In any such case,
the Company will make appropriate provision with respect to such holders’ rights and interests to insure that the provisions of
this Section 5(y) will thereafter be applicable to the Series D Preferred Shares. Nor may the Company may consummate a
reverse stock split without the prior written consent of the Investor, except with respect to the reverse stock split previously authorized
and described in the Definitive Information Statement filed with the SEC on November 27, 2020 (which action shall, for avoidance
of doubt, not be prohibited).

 

(z)            Transactions
With Affiliates. So long as the Series D Preferred and/or Commitment Shares are held by the Investor, the Company shall not,
and shall cause each of its subsidiaries not to, enter into, amend, modify or supplement, or permit any subsidiary to enter into, amend,
modify or supplement any agreement, transaction, commitment, or arrangement with any of its or any subsidiary’s officers, directors,
person who were officers or directors at any time during the previous 2 years, stockholders who beneficially own 5% or more of the Common
Stock, or Affiliates (as defined below) or with any individual related by blood, marriage, or adoption to any such individual or with
any entity in which any such entity or individual owns a 5% or more beneficial interest (each a “Related Party”), except
for (a) customary employment arrangements and benefit programs on reasonable terms, (b) any investment in an Affiliate of the
Company, (c) any agreement, transaction, commitment, or arrangement on an arms-length basis on terms no less favorable than terms
which would have been obtainable from a person other than such Related Party, (d) any agreement, transaction, commitment, or arrangement
which is approved by a majority of the disinterested directors of the Company. “Affiliate” for purposes hereof means,
with respect to any person or entity, another person or entity that, directly or indirectly, (i) has a 10% or more equity interest
in that person or entity, (ii) has 10% or more common ownership with that person or entity, (iii) controls that person or entity,
or (iv) shares common control with that person or entity. “Control” or “controls” for purposes
hereof means that a person or entity has the power, direct or indirect, to conduct or govern the policies of another person or entity.

 

(aa)          Transfer
Agent. The Company covenants and agrees that, in the event that the Company’s agency relationship with the transfer agent should
be terminated for any reason prior to a date which is 2 years after the Closing Date, the Company shall immediately appoint a new transfer
agent and shall require that the new transfer agent execute and agree to be bound by the terms of the Irrevocable Transfer Agent Instructions
(as defined herein).

 

    24

    

    

 

(bb)          Restriction
on Issuance of the Capital Stock and Prohibition on Variable Rate Transactions. Until the earlier to occur of i) 6 months from the
date hereof or ii) the Investor holds less than 325 shares Series D Preferred, the Company shall not, without the prior written consent
of the Investor, (i) issue or sell shares of Common Stock or Preferred Stock without consideration or for a consideration per share
less than the bid price of the Common Stock determined immediately prior to its issuance, (ii) issue any preferred stock, warrant,
option, right, contract, call, or other security or instrument granting the holder thereof the right to acquire Common Stock without consideration
or for a consideration less than such Common Stock’s Bid Price, as quoted by Bloomberg, LP and determined immediately prior to its
issuance, (iii) enter into any or draw down on any agreement to issue or sell, any Common Stock, Preferred Stock, options, warrants
or convertible securities that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of
Common Stock at a price which varies or may vary with the bid price or volume weighted average price of the shares of Common Stock, as
quoted by Bloomberg, LP, (iv) enter into or issue any promissory notes payable in cash, shares of the Company’s Common Stock,
preferred stock or any combination thereof, (v) enter into any security instrument granting the holder a security interest in any
and all assets of the Company, or (v) file any registration statement on Form S-8.

 

(cc)          Neither
the Investor nor any of its affiliates have an open short position in the Common Stock of the Company, and the Investor agrees that it
shall not, and that it will cause its affiliates not to, engage in any short sales of or hedging transactions with respect to the Common
Stock as long as any of the Securities shall remain outstanding.

 

(dd)          Review
of Public Disclosures. All SEC filings (including, without limitation, all filings required under the Exchange Act, which include
Forms 10-Q and 10-QSB, 10-K and 10K-SB, 8-K, etc) and other public disclosures made by the Company, including, without limitation, all
press releases, investor relations materials, and scripts of analysts meetings and calls, shall be reviewed and approved for release by
the Company’s attorneys and, if containing financial information, the Company’s independent certified public accountants.

 

(ee)          Disclosure
of Transaction. Within 4 Business Day following the date of this Agreement, the Company shall file a Current Report on Form 8-K
describing the terms of the transactions contemplated by the Transaction Documents in the form required by the Exchange Act and attaching
the material Transaction Documents (including, without limitation, this Agreement, and the form of the Warrant) as exhibits to such filing.

 

(ff)           Right
of Participation. For a period of 12 months from the date hereof, if the Company intends to raise additional capital by the issuance
or sale of, including but not limited to, shares of Common Stock, (ii) preferred stock, warrant, option, right, contract, call, or
other security or instrument granting the holder thereof the right to acquire Common Stock, preferred stock, options, warrants or any
other securities convertible or exercisable into shares of Common Stock (whether the offering is conducted by the Company, underwriter,
placement agent or any third party) the Investor shall have right to participate in such issuance or sale up to the greater of (x) fifty
(50%) or (y) $6,500,000 of the amount of such additional capital raise. The Company shall provide the Investor in writing the principal
amount of capital it intends to raise and outline of the material terms of such capital raise, simultaneous with offering such issuance
or sale of capital stock to third parties including, but not limited to, current or former officers or directors, current or former shareholders
and/or investors of the obligor, underwriters, brokers, agents or other third parties.  The Investor shall have one (1) business
days from receipt of such notice of the sale or issuance of capital stock to notify the Company of its intention to participate in all
or a portion of such capital raising offer.  For avoidance of doubt, this right shall exclude any Strategic Investment, and any offerings
or issuances where only officers and directors of the Company participate. For purposes of this section “Strategic Investment”
shall be defined as securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
from an entity whose primary business is investing in securities.

 

    25

    

    

 

6.              TRANSFER
AGENT INSTRUCTIONS.

 

The Company shall issue the Irrevocable Transfer
Agent Instructions to its transfer agent in a form acceptable to the Investor.

 

7.              CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.

 

(a)           The
obligation of the Company hereunder to issue and sell the Series D Preferred Shares, the Warrant and Commitment Shares to the Investor
at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these
conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

 

(i)            The
Investor shall have executed the Transaction Documents and delivered them to the Company.

 

(ii)           The
Investor shall have delivered to the Company the Purchase Price by wire transfer of immediately available U.S. funds pursuant to the wire
instructions provided by the Company.

 

(iii)          The
representations and warranties of the Investor shall be true and correct in all material respects as of the date when made and as of the
Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Investor
shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement
to be performed, satisfied or complied with by the Investor at or prior to the Closing Date.

 

8.              CONDITIONS
TO THE INVESTOR’S OBLIGATION TO PURCHASE.

 

(a)            The
obligation of the Investor hereunder to purchase the Series D Preferred Shares, the Warrant and Commitment Shares at the Closing
is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are
for the Investor’s sole benefit and may be waived by the Investor at any time in its sole discretion:

 

(i)             The
Company, and the Company’s Transfer Agent, as applicable, shall have executed the Transaction Documents and delivered the same to
the Investor.

 

    26

    

    

 

(ii)            The
Common Stock shall be authorized for quotation or trading on the Primary Market and trading in the Common Stock shall not have been suspended
for any reason.

 

(iii)           The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section 4 above, in which case, such representations and
warranties shall be true and correct without further qualification) as of the date when made and as of the Closing Date as though made
at that time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied
or complied with by the Company at or prior to the Closing Date.

 

(iv)           The
Company shall have filed the Certificate of Designation for the Series D Preferred Shares with the Secretary of State of the Company’s
state of incorporation and provided the Investor a stamped filed copy.

 

(v)            The
Company shall have executed and delivered to the Investor the Series D Preferred Shares, the Commitment Shares and the Warrant.

 

(vi)           The
Investor shall have received an opinion of counsel from counsel to the Company in a form satisfactory to the Investor, which shall include
but not be limited to whether the Company is an issuer defined as a “Shell Company,” as defined in paragraph (i)(1)(i) of
Rule 144 or has been at any time previously an issuer defined as a “Shell Company.”

 

(vii)          The
Company shall have delivered to the Investor a certificate, executed by an officer of the Company in a form satisfactory to the Investor
and dated as of the Closing Date, as to (i) the Company’s Article of Incorporation, (ii) the Bylaws of the Company,
(iii) the resolutions as adopted by the Company's Board of Directors in a form reasonably acceptable to the Investor, (iv) the
Company’s Certificate of Good, each as in effect at the Closing.

 

(viii)         The
Company shall have provided Investor a true copy of a certificate of good standing evidencing the formation and good standing of the Company
from the secretary of state (or comparable office) from the jurisdiction in which the Company is incorporated, as of a date within 10
days of the Closing Date.

 

(ix)           The
Company and its transfer agent shall have created the Share Reserve.

 

    27

    

    

 

9.              EVENTS
OF DEAULT.

 

An “Event of Default”, wherever used herein, means
any one of the following events (whatever the reason and whether it shall be voluntary or involuntary or effected by operation of law
or pursuant to any judgment, decree or order of any court, or any order, rule or regulation of any administrative or governmental
body):

 

(a)           The
Company shall fail to observe or perform any covenant, agreement or warranty contained in, or otherwise commit any breach or default of
any provision contained herein or in any Transaction Document which is not cured within any applicable cure period;

 

(b)           The
Company or any subsidiary of the Company shall commence, or there shall be commenced against the Company or any subsidiary of the Company
under any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Company or any subsidiary
of the Company commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Company or any subsidiary
of the Company or there is commenced against the Company or any subsidiary of the Company any such bankruptcy, insolvency or other proceeding
which remains undismissed for a period of 61 days; or the Company or any subsidiary of the Company is adjudicated insolvent or bankrupt;
or any order of relief or other order approving any such case or proceeding is entered; or the Company or any subsidiary of the Company
suffers any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of its property
which continues undischarged or unstayed for a period of 61 days; or the Company or any subsidiary of the Company makes a general assignment
for the benefit of creditors; or the Company or any subsidiary of the Company shall fail to pay, or shall state that it is unable to pay,
or shall be unable to pay, its debts generally as they become due; or the Company or any subsidiary of the Company shall call a meeting
of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Company or any subsidiary of
the Company shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing;
or any corporate or other action is taken by the Company or any subsidiary of the Company for the purpose of effecting any of the foregoing;

 

(c)           The
Company or any subsidiary of the Company shall default in any of its obligations under any other obligation or any mortgage, credit agreement
or other facility, indenture agreement, factoring agreement or other instrument under which there may be issued, or by which there may
be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement of the Company
or any subsidiary of the Company in an amount exceeding One Hundred Thousand Dollars ($100,000), whether such indebtedness now exists
or shall hereafter be created and such default shall result in such indebtedness becoming or being declared due and payable prior to the
date on which it would otherwise become due and payable;

 

(d)           The
Common Stock shall cease to be quoted for trading or listed for trading on the Primary Market or such subsequent market upon which the
Common Stock becomes quoted for trading or listed. and shall not again be quoted or listed for trading thereon within 5 Trading Days of
such delisting; or

 

    28

    

    

 

 

(e)            The
Company shall fail for any reason to deliver Common Stock certificates to a within 3 Trading Day after a conversion or the Company shall
provide notice to the Holder, including by way of public announcement, at any time, of its intention not to comply with requests for conversions
of the Series A Preferred Shares in accordance with the terms hereof.

 

10.  INDEMNIFICATION

 

(a)            In
consideration of the Investor’s execution and delivery of this Agreement and acquiring the Series D Preferred Shares, the Commitment
Shares, the Conversion Shares upon conversion of the Series D Preferred Shares, the Warrant and the Warrant Shares upon exercise
of the Warrant and in addition to all of the Company’s other obligations under this Agreement, the Company shall defend, protect,
indemnify and hold harmless the Investor, and all of their officers, directors, employees and agents (including, without limitation,
those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Investor Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Investor Indemnitee is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred
by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (a) any misrepresentation or breach
of any representation or warranty made by the Company in this Agreement, the Certificate of Designations or the other Transaction Documents
or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation
of the Company contained in this Agreement, or the other Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, or (c) any cause of action, suit or claim brought or made against such Investor Indemnitee and arising out of
or resulting from the execution, delivery, performance or enforcement of this Agreement or any other instrument, document or agreement
executed pursuant hereto by any of the parties hereto, any transaction financed or to be financed in whole or in part, directly or indirectly,
with the proceeds of the issuance of the Series D Preferred Shares and the Commitment Shares or the status of the Investor or holder
of the Series D Preferred Shares, the Conversion Shares and the Commitment Shares, as an Investor of Series D Preferred Shares
and the Commitment Shares in the Company. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason,
the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible
under applicable law.

 

    29

    

    

(b)            In
consideration of the Company’s execution and delivery of this Agreement, and in addition to all of the Investor’s other obligations
under this Agreement, the Investor shall defend, protect, indemnify and hold harmless the Company and all of its officers, directors,
employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the “Company Indemnitees”) from and against any and all Indemnified Liabilities incurred by the Indemnitees
or any of them as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty
made by the Investor(s) in this Agreement, instrument or document contemplated hereby or thereby executed by the Investor, (b) any
breach of any covenant, agreement or obligation of the Investor(s) contained in this Agreement, the Transaction Documents or any
other certificate, instrument or document contemplated hereby or thereby executed by the Investor, or (c) any cause of action, suit
or claim brought or made against such Company Indemnitee based on material misrepresentations or due to a material breach and arising
out of or resulting from the execution, delivery, performance or enforcement of this Agreement, the Transaction Documents or any other
instrument, document or agreement executed pursuant hereto by any of the parties hereto. To the extent that the foregoing undertaking
by the Investor may be unenforceable for any reason, the Investor shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities, which is permissible under applicable law.

 

(c)            The
foregoing indemnity provisions of the Company and the Investor shall not apply to the extent that the indemnified liabilities result from
gross negligence or willful misconduct of the party seeking indemnification hereunder.

 

11.  GOVERNING
LAW: MISCELLANEOUS.

 

(a)         Governing
Law; Mandatory Jurisdiction. TO INDUCE INVESTOR TO PURCHASE THE SECURITIES, THE COMPANY IRREVOCABLY AGREES THAT ANY DISPUTE ARISING
UNDER, RELATING TO, OR IN CONNECTION WITH, DIRECTLY OR INDIRECTLY, THIS AGREEMENT OR RELATED TO ANY MATTER WHICH IS THE SUBJECT OF OR
INCIDENTAL TO THIS AGREEMENT ANY OTHER TRANSACTION DOCUMENT (WHETHER OR NOT SUCH CLAIM IS BASED UPON BREACH OF CONTRACT OR TORT) SHALL
BE SUBJECT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE STATE COURTS SITTING IN UNION COUNTY, NEW JERSEY AND THE FEDERAL COURTS SITTING
IN NEWARK, NEW JERSEY; PROVIDED, HOWEVER, INVESTOR MAY, AT ITS SOLE OPTION, ELECT TO BRING ANY ACTION IN ANY OTHER JURISDICTION.
THIS PROVISION IS INTENDED TO BE A “MANDATORY” FORUM SELECTION CLAUSE AND GOVERNED BY AND INTERPRETED CONSISTENT WITH NEW
JERSEY LAW. THE COMPANY HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION AND VENUE OF ANY STATE OR FEDERAL COURT HAVING ITS SITUS IN SAID
COUNTY, AND WAIVES ANY OBJECTION BASED ON FORUM NON CONVENIENS. THE COMPANY HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND
CONSENT THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, DIRECTED TO THE COMPANY AS SET
FORTH HEREIN IN THE MANNER PROVIDED BY APPLICABLE STATUTE, LAW, RULE OF COURT OR OTHERWISE

 

(b)            Counterparts.
This Agreement may be executed in 2 or more identical counterparts, all of which shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and physically or electronically delivered to the other party.

 

(c)          Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

    30

    

    

(d)            Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction.

 

(e)           Entire
Agreement, Amendments. This Agreement supersedes all other prior oral or written agreements between the Investor, the Company, their
affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, neither the Company nor any Investor makes any representation, warranty, covenant or undertaking with respect
to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to
be charged with enforcement.

 

12.  Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered upon: (i) receipt, when delivered personally, (ii) 1 Business Day
after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to
receive the same, or (iii) receipt, when sent by electronic mail (provided that the electronic mail transmission is not
returned in error or the sender is not otherwise notified of any error in transmission. The addresses and e-mail addresses for such
communications shall be:

 

	If to the Company, to:	KULR Technology Group, Inc.
	 	1999 S. Bascom Ave., Suite 700
	 	Campbell, CA 95008
	 	Attention:	Michael Mo
	 	Telephone:	(408) 663-5247
	 	Email:	Michael.mo@kulrtechnology.com
	 	 
	 	 
	With a copy (which notice shall not constitute notice) to:  	Sichenzia Ross Ference LLP
	 	1185 Avenue of the Americas, 31st Floor
	 	New York, NY 10036
	 	 
	 	Attention:	Jay Yamamoto
	 	Telephone:	(212) 930-9700
	 	Email: jyamamotoo@srf.law
	 	 

 

	If to the Investor:	YA II PN, Ltd.
	 	c/o Yorkville Advisors Global, LP
	 	1012 Springfield Avenue
	 	Mountainside, NJ  07092
	 	Attention:	Mark Angelo
	 	Telephone:	(201) 536-5114
	 	Email: mangelo@yorkvilleadvisors.com
	 	 
	With a copy to:	David Gonzalez, Esq. 
	 	1012 Springfield Avenue
	 	Mountainside, NJ  07092
	 	Telephone:	(201) 536-5109
	 	Email:  dgonzalez@yorkvilleadvisors.com

 

    31

    

    

or at such other address and/or electronic email
address and/or to the attention of such other person as the recipient party has specified by written notice given to each other party
3 Business Days prior to the effectiveness of such change. Written confirmation of receipt (i) given by the recipient of such notice,
consent, waiver or other communication, (ii) mechanically or electronically generated by the sender’s computer containing the
time, date, recipient’s electronic mail address and the text of such electronic mail or (iii) provided by a nationally recognized
overnight delivery service, shall be rebuttable evidence of personal service, receipt by electronic mail or receipt from a nationally
recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(a)          Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
Neither the Company nor any Investor shall assign this Agreement or any rights or obligations hereunder without the prior written consent
of the other party hereto.

 

(b)          No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

(c)          Survival.
Unless this Agreement is terminated under Section 11(f), all agreements, representations and warranties contained in this Agreement
or made in writing by or on behalf of any party in connection with the transactions contemplated by this Agreement shall survive the execution
and delivery of this Agreement and the Closing.

 

(d)          Publicity.
The Company and the Investor shall have the right to approve, before issuance any press release or any other public statement with respect
to the transactions contemplated hereby made by any party; provided, however, that the Company shall be entitled, without the prior approval
of the Investor, to issue any press release or other public disclosure with respect to such transactions required under applicable securities
or other laws or regulations (the Company shall use its best efforts to consult the Investor in connection with any such press release
or other public disclosure prior to its release and Investor shall be provided with a copy thereof upon release thereof).

 

(e)            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(f)            Termination.
In the event that the Closing shall not have occurred on or before 5th business days from the date hereof due to the Company’s
or the Investor’s failure to satisfy the conditions set forth in Sections 7 and 8 above (and the non-breaching party’s failure
to waive such unsatisfied condition(s)), the non-breaching party shall have the option to terminate this Agreement with respect to such
breaching party at the close of business on such date without liability of any party to any other party.

 

    32

    

    

(g)            Brokerage.
The Company represents that other than Maxim Group, LLC no broker, agent, finder or other party has been retained by it in connection
with the transactions contemplated hereby and that no other fee or commission has been agreed by the Company to be paid for or on account
of the transactions contemplated hereby.

 

(h)            No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.

 

[REMAINDER PAGE INTENTIONALLY LEFT BLANK]

 

    33

    

    

IN
WITNESS WHEREOF, each of the Investor and the Company has affixed their respective signatures to this Securities Purchase
Agreement as of the date first written above.

 

		COMPANY:
	 	 
		KULR TECHNOLOGY GROUP, INC.
	 	 
		By:	 
		Name:
		Title:
	 	 
		INVESTOR:
	 	 
		YA II PN, LTD.
	
	By:     Yorkville Advisors Global,
    LP
	 	Its:     Investment Manager
	
	 
	 	By:    Yorkville Advisors Global
    II, LLC
	 	Its:     General Partner
	 	 
	 	By:	 
		Name:	 
	 	Title:	 

 

    34

    

    

LIST OF EXHIBITS:

 

Disclosure Schedule

 

Exhibit A – Certificate of Designation

Exhibit B – Form of Warrant

 

    

     

    

DISCLOSURE SCHEDULE

 

Schedule 4(a) – Subsidiaries

 

		•	KULR Technology Corporation, a Delaware Corporation

 

Schedule 4(b) – Security Interests
Granted

 

		•	None

 

Schedule 4(e)– Capitalization

 

		•	None

 

Schedule 4(ii) – Registration Rights

 

		•	See rights granted in connection with the following financings:

 

		o	https://www.sec.gov/Archives/edgar/data/1662684/000110465920029207/tm2011733-2_424b5.htm

 

		o	https://www.sec.gov/Archives/edgar/data/1662684/000110465920140591/tm2039616d1_424b5.htm

 

    

     

    

EXHIBIT A

 

    

     

    

EXHIBIT BExhibit 10.2

 

EXECUTION VERSION

 

COMMON STOCK PURCHASE WARRANT

 

kulr
technology group, inc.

 

	Warrant Shares: 2,600,000	Issuance Date: May 20, 2021

 

THIS COMMON STOCK PURCHASE WARRANT
(the “Warrant”) certifies that, for value received, YAII PN, Ltd. or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Issuance Date”) and on or prior to 5:00 p.m. (New York City time) on May 19, 2022 (the
 “Termination Date”) but not thereafter, to subscribe for and purchase from KULR Technology Group, Inc., a Delaware
corporation (the “Company”), up to 2,600,000 shares (as subject to adjustment hereunder, the “Warrant Shares”)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).

 

Section 1.        Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the “Purchase Agreement”), dated May 19, 2021, among the Company and the Holder.

 

Section 2.         Exercise.

 

a)       Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Issuance Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail
(or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the
earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price
for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No
ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any
Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.

 

    1

    

    

 

b)      Exercise
Price. The exercise price per share of Common Stock under this Warrant shall be $2.50, subject to adjustment hereunder
(the “Exercise Price”).

 

c)      Cashless
Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)	=	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;
	 	 	 	 
	 	(B)	=	the Exercise Price of this Warrant, as adjusted hereunder; and

 

    2

    

    

 

	 	(X)	=	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of
the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.  The Company
agrees not to take any position contrary to this Section 2(c).

 

“Bid Price”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New
York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.

 

    3

    

    

 

		d)	Mechanics of Exercise.

 

i.        Delivery
of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder as outlined in the Irrevocable Transfer Agent Instructions dated May 18, 2021 (the “Transfer Agent Instructions”),
among the Company and the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one
(1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery
Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery
of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each
Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.
As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading
Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice
of Exercise.

 

ii.      Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.

 

    4

    

    

 

iii.    Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.     Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.

 

    5

    

    

 

v.        No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

vi.      Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.     Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    6

    

    

 

		e)	Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates
(such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below).  For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or
Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth
in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e),
in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a
more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this
Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant.

 

    7

    

    

 

Section 3.         Certain
Adjustments.

 

a)       Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.

 

b)       Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent
that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c)       Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however,
that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).

 

    8

    

    

 

 

d)            Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
voting securities, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding voting securities (not including voting securities held by the other Person or other Persons making or party to,
or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the
right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this
Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if
such Successor Entity had been named as the Company herein.

  

e)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)            Notice
to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

  

    9

    

    

 

ii.            Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.

  

Section 4.            Transfer
of Warrant.

 

a)          Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.

 

    10

    

    

 

b)            New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)          Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

Section 5.              Miscellaneous.

 

a)          No
Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.

 

b)          Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

    11

    

    

 

c)            Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.

 

d)            Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

  

Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    12

    

    

 

Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

e)            Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.

 

f)            Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

  

g)            Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h)            Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i)           Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

j)            Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k)            Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

    13

    

    

 

l)            Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)          Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

  

n)            Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.

 

********************

 

(Signature Page Follows)

    14

    

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

		kulr
    technology group, inc. 
	 	 
	 	 
		By: 	 
			Name:
			Title:

  

    15

    

    

 

NOTICE OF EXERCISE

 

To:     kulr
technology group, inc.

 

(1)            The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)            Payment
shall take the form of (check applicable box):

 

 ̈
in lawful money of the United States; or

 

 ̈ [if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).

 

(3)          Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The Warrant Shares shall be delivered to the
following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: ________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

 

Name of Authorized Signatory: ___________________________________________________________________

 

Title of Authorized Signatory: ____________________________________________________________________

 

Date: ________________________________________________________________________________________

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to

  

	Name:	 
	 	(Please Print)
	 	 
	Address: 	 
	 	(Please Print)
	 	 
	Phone Number: 	 
	 	 
	Email Address: 	 
	 	 
	Dated: _______________
    __, ______	 
	 	 
	Holder’s Signature:                                               	 
	 	 
	Holder’s Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]